(603811)"Zhejiang Cheng Yi Pharmaceutical Co., Ltd."Announcement on Key Operating Data for Q3 2026
Filed with SSE · Stock code 603811 · · 2 pages · Chinese
Summary by 6ix AI
The report details the company's revenue and costs across various sectors and products, highlighting performance in the pharmaceutical manufacturing industry. It includes specific figures for different product categories, such as formulations and raw materials, along with their respective profit margins. The announcement also breaks down revenue by treatment area and geographical region, providing insights into domestic and international sales.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Zhejiang Chengyi Pharmaceutical Co. Ltd. on 6ix
Story so far
Earlier from Zhejiang Chengyi Pharmaceutical
- (603811)"Zhejiang Cheng Yi Pharmaceutical Co., Ltd."Announcement on Results of Shareholding Reduction by Director and Senior Executive
- Announcement on Results of Shareholding Reduction by Senior Executive
- Announcement on a Subsidiary's Receipt of Drug GMP Compliance Inspection Results
- Announcement on Outline of the 2026 Semi-annual Performance Briefing
- Announcement on Satisfaction of Unlocking Conditions for the 1st Unlocking Period under the 2025 Employee Stock Ownership Plan
Follow Zhejiang Chengyi Pharmaceutical into a list and get an email when it puts out news.
Follow Zhejiang Chengyi Pharmaceutical